AUS
NZ
UK
CA
USA
IND
Highlights
-Analysts rate Cencora as Moderate Buy.
-Executives report significant share sales.
-Institutional ownership stands at 97.52%.
Cencora Inc. stands as a prominent player in the NYSE Healthcare Stock sector, delivering pharmaceutical distribution and solutions to a diverse range of clients. Recent analyst evaluations provide a "Moderate Buy" consensus, reflecting confidence in the company’s growth prospects. Insider activity and strong institutional backing further highlight Cencora's market relevance and stability.
Cencora Inc. (NYSE:COR): Analysts' Consensus and Target Price
Cencora, Inc. has garnered a consensus "Moderate Buy" rating from 11 analysts covering the stock. With eight analysts issuing a "Buy" rating and three opting for "Hold," the sentiment reflects cautious optimism. The average 12-month target price stands at $271.20, indicating strong confidence in the company's long-term performance.
Insider Transactions: Key Developments
Notable insider transactions have drawn attention, including the sale of over 21,000 shares by Chairman Steven H. Collis. This move, representing a 7.02% reduction in his holdings, underscores ongoing activity among company executives. Such disclosures provide transparency and offer a glimpse into management’s perspective on the company’s trajectory.
Institutional Activity in Cencora
Institutional investors have maintained significant stakes in Cencora. In recent months, major hedge funds and financial institutions have either expanded or adjusted their holdings. For instance, entities like Geode Capital Management and Concord Wealth Partners have bolstered their positions, indicating continued confidence in the firm’s potential.
Performance Metrics and Financial Health
Cencora’s financial metrics showcase stability and growth. The stock opened at $245.02 on Monday, with a market capitalization of $48.28 billion. Its price-to-earnings (P/E) ratio of 32.63 and a PEG ratio of 1.63 highlight the balance between valuation and growth. With a current ratio of 0.88 and a quick ratio of 0.53, Cencora demonstrates sound liquidity management.
The company’s shares have experienced steady upward momentum, trading between a 1-year low of $195.83 and a high of $251.56. The 50-day moving average price of $233.22 and the 200-day average of $231.65 further reflect consistent performance.
Dividend Growth
Cencora recently announced an increased quarterly dividend of $0.55 per share, representing a positive change from the previous payout. The annualized dividend yield now stands at 0.90%, reflecting the company’s commitment to returning value to shareholders while maintaining a payout ratio of 29.29%.
Operational Excellence
Cencora operates across multiple healthcare domains, sourcing and distributing pharmaceutical products. The U.S. Healthcare Solutions segment plays a pivotal role, catering to hospitals, pharmacies, and medical clinics. Its diverse services include pharmacy management, packaging solutions, clinical trial support, and data analytics. Additionally, the company serves the veterinary market with pharmaceuticals and diagnostics, ensuring a wide-reaching presence.
Cencora, Inc. continues to maintain its standing as a prominent player in the pharmaceutical distribution and healthcare services sector. Strong institutional backing, favorable analyst ratings, and robust operational capabilities position it as a noteworthy entity in the financial landscape.
